For how we live.
A modelling study of Koungou village, calibrated to daily cases by vaccination status, estimates CVD 103-HgR prevented 87% of cholera and averted hundreds of cases — a first real-world test of a challenge-trial vaccine.
A case-control study of young children during a statewide whooping-cough outbreak found three or more DTaP doses cut the odds of pertussis by more than 25-fold against unvaccinated peers.
A prespecified analysis of 131,276 older adults found RSVpreF cut RSV hospitalisations overall. In the immunosuppressed, baseline risk was nine times higher — but the subgroup was too small to prove it helped them.
In a 366-child phase 2b trial, the live attenuated nasal vaccine BPZE1 raised the mucosal antibody current shots miss, and did not blunt a co-given Tdap. The maker funded the study.
A government-funded test-negative study put effectiveness at 86% against emergency visits and 88% against intensive care, though the smallest subgroups carried wide confidence intervals.
A test-negative study across seven paediatric hospitals in Ontario and Quebec, run after a publicly funded rollout, estimated 78% effectiveness against laboratory-confirmed RSV and 97% against intensive-care admission.
A cluster-randomised trial in nearly 2,000 US nursing homes found fewer confirmed influenza outbreaks with a recombinant vaccine in a moderate flu season, but no difference in a near-flu-free one.
A US analysis of the 2025-2026 vaccines targeting the LP.8.1 lineage found both an mRNA-1283 and a BNT162b2 shot reduced COVID hospitalisation in older adults, with the strongest effect in those aged 75 and over.
Two randomised UK trials tested giving the vaccines together. Systemic reactions stayed mostly mild and immune responses held up, though one trial saw more sore arms and a dip in COVID antibodies with co-administration.
The injected vaccine contains no live virus. In a Cochrane review, inactivated vaccines raised fever only from 1.5% to 2.3%, and a randomised crossover trial found no excess systemic symptoms over saline placebo.
WHO flagged a drifted A(H3N2) subclade K in December; the first 2025-2026 effectiveness data, from 1.4 million US veterans, put overall protection near 22% and protection against hospitalisation near 32%.
A 1,784-child randomised trial in Uganda found one-fifth and one-half doses of the 17DD vaccine matched the full dose for initial immunity — evidence for dose-sparing in young children when supplies run short.
A vaccine given in 2017 still cut cholera risk 78% five years on, new data show — even as collapsing water and health services let the outbreak spread through Artibonite and Centre.
JAMA published paired systematic reviews for the coming respiratory season. Both found vaccines reduced hospitalisation across age groups, with no new safety signals, though protection wanes over time.
Across 166,390 tests during Brazil's outbreak, two TAK-003 doses were 73% effective against symptomatic dengue and 88% against hospitalisation, with no sign of waning.
Two pragmatic randomised trials and a Medicare nursing home cohort landed in the same week. Together they show real protection against hospitalisation and a durability question nobody has answered.
Three surveillance networks put 2025/26 effectiveness between 22% and 45% against a drifted H3N2 virus. The figure is a comparison between vaccinated and unvaccinated people who all got tested.
A case-control study by MSF's Epicentre and WHO put NmCV-5's adjusted effectiveness at 92% against meningococcal meningitis after 2024 campaigns in Niger — on a small sample of 17 confirmed cases.
Two national studies settle the question the trials could not: in England, cancer rates fell 87% among those vaccinated at 12-13; in Sweden, the risk was cut by nearly two-thirds.
Pooling the trials, one- and two-dose HPV schedules produced lower antibody titres than three doses but still cut persistent infection — with the usual caveat about surrogate endpoints.
A national database of ~90% of public facilities found all-cause diarrhoea incidence in under-fives dropped 50% and hospitalisations 58% after 2020, with no rise in intussusception.
Two vaccines cut RSV lower-respiratory illness in older adults by roughly two-thirds to four-fifths in their pivotal trials. US guidance now recommends them for everyone 75 and older and for high-risk adults from 50.
New conjugate vaccines replaced a confusing two-shot sequence with a single dose. The efficacy evidence is solid for the older conjugate; the newest ones ride on immune-response data, not their own outcome trials.
A test-negative study found the TYPHIBEV conjugate vaccine 89% effective against confirmed typhoid in Nepali children over 30 months, with weaker and far less certain protection under age five.
In a 20,000-child trial across eight endemic countries, TAK-003 was 61.2% effective against symptomatic dengue and 84.1% against hospitalisation — but protection was narrower in children never previously infected.
In its pivotal trials the recombinant vaccine cut shingles cases by about 90 to 97 percent. Guidelines recommend two doses for adults from age 50, and for immunocompromised adults from 19.
A Buenos Aires surveillance cohort estimates 80.8% effectiveness against RSV hospitalisation in infants under three months — close to what the licensing trial found, in a real programme.